Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease
Author(s) -
AnneSophie Gille,
Corinne Pondarré,
JeanHugues Dalle,
Françoise Bernaudin,
Céline Chalas,
Mony Fahd,
C Jean,
Harry Lezeau,
Lydia Riou,
Véronique Drouineaud,
Annabel PayeJaouen,
Annie Kamdem,
Bénédicte Neven,
Cécile Arnaud,
Saba Azarnoush,
Karima Yakouben,
Sabine Sarnacki,
Mariane de Montalembert,
Éva Compérat,
Gilles Lenaour,
Mathilde Sibony,
Nathalie Dhédin,
Daniel Vaiman,
JeanPhilippe Wolf,
Catherine Patrat,
Pierre Fouchet,
Catherine Poirot,
Virginie BarraudLange
Publication year - 2020
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2020008146
Subject(s) - disease , hydroxycarbamide , sickle cell anemia , fertility , affect (linguistics) , physiology , sperm , biology , young adult , medicine , andrology , endocrinology , psychology , population , environmental health , communication
In these two short reports, the authors approach the issue of whether hydroxyurea (HU) use in young males has major irreversible effects on sperm production. Joseph et al analyzed and compared sperm parameters in male patients with sickle cell disease (SCD) who were exposed or not exposed to HU before puberty. They report semen abnormalities in all patients but no differences between groups. Independently, Gille et al provide evidence for the lack of in vivo HU-related decreases in the spermatogonial pool in biopsy specimens from young males with SCD but evidence for a negative effect of SCD itself. Together, these reports suggest that the use of HU in young males does not adversely affect fertility.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom